Zhou Y, Yang Q-W, Xiong H-Y
Department of Military Epidemiology, The Third Military Medical University, and Department of Neurology, Daping Hospital, Chongqing, China.
J Int Med Res. 2012;40(1):18-27. doi: 10.1177/147323001204000103.
Intracranial artery stenosis can be fatal, requiring fast, safe and effective intervention. The introduction of the Wingspan™ stent system with Gateway™ percutaneous transluminal angioplasty balloon catheter has made intracranial intervention possible in a clinical trial setting. This systematic review planned to identify and review all randomized controlled trials comparing angioplasty and stenting of intracranial arteries with standard medical care.
Electronic databases and relevant records were examined for possible trials using predefined inclusion and exclusion criteria.
A total of 3661 records were identified by searching several English language databases and other sources including Chinese academic journals. The recently discontinued Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial was the single qualifying study and showed clear advantage of medical management over percutaneous transluminal angioplasty and stenting (PTAS).
The SAMPRASS trial indicated that PTAS is associated with high complication and morbidity rates. Definitive recommendations cannot be made until convincing results from additional robustly designed randomized trials become available.
颅内动脉狭窄可能致命,需要快速、安全且有效的干预措施。Wingspan™支架系统与Gateway™经皮腔内血管成形术球囊导管的引入,使得在临床试验环境中进行颅内干预成为可能。本系统评价旨在识别和综述所有比较颅内动脉血管成形术和支架置入术与标准药物治疗的随机对照试验。
使用预定义的纳入和排除标准,对电子数据库和相关记录进行检查,以寻找可能的试验。
通过检索多个英文数据库和包括中国学术期刊在内的其他来源,共识别出3661条记录。最近停止的颅内狭窄预防复发性卒中的支架置入与积极药物治疗(SAMMPRIS)试验是唯一符合条件的研究,该研究表明药物治疗优于经皮腔内血管成形术和支架置入术(PTAS)。
SAMPRASS试验表明,PTAS与高并发症和发病率相关。在获得其他设计严谨的随机试验的令人信服的结果之前,无法给出明确的建议。